Table 1 Goals recommended by the latest European Society of Cardiology/European Respiratory Society guidelines for pulmonary hypertension

Better prognosis	Determinants of prognosis	Worse prognosis
No	Clinical evidence of RV failure	Yes
Slow	Rate of progression of symptoms	Rapid
No	Syncope	Yes
I and II	WHO FC	IV
Longer (>500 m)^#	6MWT	Shorter (<300 m)
Peak V′_O₂ >15 mL·min⁻¹·kg⁻¹	Cardiopulmonary exercise testing	Peak V′_O₂ <12 mL·min⁻¹·kg⁻¹
Normal or near normal	BNP/NT-proBNP plasma levels	Very elevated and rising
No pericardial effusion TAPSE^¶ >2.0 cm	Echocardiographic findings^¶	Pericardial effusion TAPSE^¶ <1.5 cm
RAP <8 mmHg and CI ≥2.5 L·min⁻¹·m⁻²	Haemodynamics	RAP >15 mmHg or CI ≤2.0 L·min⁻¹·m⁻²

RV: right ventricle; WHO FC: World Health Organization functional class; 6MWT: 6-min walking test; V′_O₂: oxygen uptake; BNP: brain natriuretic peptide; TAPSE: tricuspid annular plane systolic excursion; RAP: right arterial pressure; CI: cardiac index. ^#: depending on age; ^¶: TAPSE and pericardial effusion have been selected as they can be measured in the majority of patients. Reproduced from [4] with permission from the publisher.